News & Announcements

Weil Advised Sanofi in its €3.9 Billion Acquisition of Ablynx

Weil advised Sanofi in its €3.9 billion acquisition of Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®. Under the terms of the agreement, Sanofi acquired all of the outstanding ordinary shares of Ablynx, including shares represented by American Depositary Shares (ADSs) and warrants and convertible bonds for €45 per share in cash. 

The Weil team that advised Sanofi was led by Corporate Chairman and Mergers & Acquisitions partner Michael Aiello and included Mergers & Acquisitions partner Matthew Gilroy; Mergers & Acquisitions associates Aileen KimRob CohenGeoffrey Weinberg and Mario Carroll; Technology & IP Transactions partner Jeffrey Osterman; Banking & Finance partners Olivier Jauffret and Daniel Dokos; Public Company Advisory Group partner Adé Heyliger; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; Technology & IP Transactions associates Caroline GeigerChristine Paik and Rami Sherman; Antitrust associate Natalie Hayes; and Banking & Finance associate Kalish Mullen.

Legalese